Fecal Matrix Metalloprotease-9 and Lipocalin-2 as Biomarkers in Detecting Endoscopic Activity in Patients With Inflammatory Bowel Diseases.

Related Articles Fecal Matrix Metalloprotease-9 and Lipocalin-2 as Biomarkers in Detecting Endoscopic Activity in Patients With Inflammatory Bowel Diseases. J Clin Gastroenterol. 2017 Jul 18;: Authors: Buisson A, Vazeille E, Minet-Quinard R, Goutte M, Bouvier D, Goutorbe F, Pereira B, Barnich N, Bommelaer G Abstract BACKGROUND: Fecal biomarkers are emerging tools in the assessment of mucosal healing in inflammatory bowel diseases (IBD). GOALS: We aimed to evaluate the accuracy of fecal matrix metalloprotease-9 (MMP-9) and fecal lipocalin-2 (LCN-2) compared with calprotectin in detecting endoscopic activity in IBD STUDY:: Overall, 86…

Read More

Telemedicine for management of inflammatory bowel disease (myIBDcoach): a pragmatic, multicentre, randomised controlled trial.

Related Articles Telemedicine for management of inflammatory bowel disease (myIBDcoach): a pragmatic, multicentre, randomised controlled trial. Lancet. 2017 Jul 14;: Authors: de Jong MJ, van der Meulen-de Jong AE, Romberg-Camps MJ, Becx MC, Maljaars JP, Cilissen M, van Bodegraven AA, Mahmmod N, Markus T, Hameeteman WM, Dijkstra G, Masclee AA, Boonen A, Winkens B, van Tubergen A, Jonkers DM, Pierik MJ Abstract BACKGROUND: Tight and personalised control of inflammatory bowel disease in a traditional setting is challenging because of the disease complexity, high pressure on outpatient clinics, and rising incidence….

Read More

Role of new endoscopic techniques in inflammatory bowel disease management: Has the change come?

Role of new endoscopic techniques in inflammatory bowel disease management: Has the change come? World J Gastroenterol. 2017 Jun 28;23(24):4324-4329 Authors: Goran L, Negreanu L, Negreanu AM Abstract Despite significant therapeutic progress in recent years, inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, remains a challenge regarding its pathogenesis and long-term complications. New concepts have emerged in the management of this disease, such as the “treat-to-target” concept, in which mucosal healing plays a key role in the evolution of IBD, the risk of recurrence and the need…

Read More

Incidence and Management of Recurrence in Patients with Crohn’s Disease Who Have Undergone Intestinal Resection: The Practicrohn Study.

Incidence and Management of Recurrence in Patients with Crohn’s Disease Who Have Undergone Intestinal Resection: The Practicrohn Study. Inflamm Bowel Dis. 2017 Jun 20;: Authors: Domènech E, Garcia V, Iborra M, Gutiérrez A, García-López S, Martín Arranz MD, Garcia-Planella E, Calvo M, Castro L, Mínguez M, Taxonera C, Juliá B, Cea-Calvo L, Romero C, Barreiro-de Acosta M Abstract BACKGROUND: More than 50% of patients with Crohn’s disease require intestinal resection at least once. Postoperative recurrence (POR) is almost uniform if prophylactic treatment is not started early. Endoscopic monitoring is generally…

Read More

Noninvasive Fecal Immunochemical Testing and Fecal Calprotectin Predict Mucosal Healing in Inflammatory Bowel Disease: A Prospective Cohort Study.

Noninvasive Fecal Immunochemical Testing and Fecal Calprotectin Predict Mucosal Healing in Inflammatory Bowel Disease: A Prospective Cohort Study. Inflamm Bowel Dis. 2017 Jun 20;: Authors: Ma C, Lumb R, Walker EV, Foshaug RR, Dang TT, Verma S, Huang VW, Kroeker KI, Wong K, Dieleman LA, Fedorak RN, Halloran BP Abstract BACKGROUND: The noninvasive biomarkers fecal immunochemical testing (FIT) and fecal calprotectin (FCP) are sensitive for prediction of mucosal inflammation in inflammatory bowel disease. However, neither test has yet been shown to independently and accurately predict mucosal healing (MH). We aimed…

Read More

Individualized Infliximab Treatment Guided by Patient-managed eHealth in Children and Adolescents with Inflammatory Bowel Disease.

Individualized Infliximab Treatment Guided by Patient-managed eHealth in Children and Adolescents with Inflammatory Bowel Disease. Inflamm Bowel Dis. 2017 Jun 14;: Authors: Carlsen K, Houen G, Jakobsen C, Kallemose T, Paerregaard A, Riis LB, Munkholm P, Wewer V Abstract BACKGROUND: To individualize timing of infliximab (IFX) treatment in children and adolescents with inflammatory bowel disease (IBD) using a patient-managed eHealth program. METHODS: Patients with IBD, 10 to 17 years old, treated with IFX were prospectively included. Starting 4 weeks after their last infusion, patients reported a weekly symptom score and…

Read More

Agreement Between Home-based Measurement of Stool Calprotectin and ELISA Results for Monitoring Inflammatory Bowel Disease Activity.

Agreement Between Home-based Measurement of Stool Calprotectin and ELISA Results for Monitoring Inflammatory Bowel Disease Activity. Clin Gastroenterol Hepatol. 2017 Jun 09;: Authors: Heida A, Knol M, Kobold AM, Bootsman J, Dijkstra G, van Rheenen PF Abstract BACKGROUND AND AIMS: An increasing number of physicians use repeated measurements of stool calprotectin to monitor intestinal inflammation in patients with inflammatory bowel diseases (IBD). A lateral flow-based rapid test allows patients to measure their own stool calprotectin values at home. The test comes with a software application (IBDoc) that turns a smartphone…

Read More

Fecal Calprotectin Levels Predict Histological Healing in Ulcerative Colitis.

Fecal Calprotectin Levels Predict Histological Healing in Ulcerative Colitis. Inflamm Bowel Dis. 2017 Jun 05;: Authors: Patel A, Panchal H, Dubinsky MC Abstract BACKGROUND: Mucosal healing as measured by endoscopic activity is the therapeutic target for ulcerative colitis (UC) and associated with improved outcomes. We investigated the clinical utility of fecal calprotectin (FC) levels to predict depth of remission, including histological remission in patients with UC. METHODS: We performed a retrospective chart review of patients with UC who underwent a full colonoscopy and FC measured within 6 weeks before colonoscopy…

Read More

Comparative Acceptability and Perceived Clinical Utility of Monitoring Tools: A Nationwide Survey of Patients with Inflammatory Bowel Disease.

Comparative Acceptability and Perceived Clinical Utility of Monitoring Tools: A Nationwide Survey of Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis. 2017 May 24;: Authors: Buisson A, Gonzalez F, Poullenot F, Nancey S, Sollellis E, Fumery M, Pariente B, Flamant M, Trang-Poisson C, Bonnaud G, Mathieu S, Thevenin A, Duruy M, Filippi J, Lʼhopital F, Luneau F, Michalet V, Genès J, Achim A, Cruzille E, Bommelaer G, Laharie D, Peyrin-Biroulet L, Pereira B, Nachury M, Bouguen G, ACCEPT study group Abstract BACKGROUND: Objective control of intestinal inflammation during inflammatory bowel…

Read More

Reply to: Accuracy of Consecutive Fecal Calprotectin Measurements to Predict Relapse in Inflammatory Bowel Disease Patients.

Reply to: Accuracy of Consecutive Fecal Calprotectin Measurements to Predict Relapse in Inflammatory Bowel Disease Patients. J Clin Gastroenterol. 2017 May 17;: Authors: Ferreiro-Iglesias R, Barreiro-de Acosta M, Dominguez-Munoz JE PMID: 28520581 [PubMed – as supplied by publisher] PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/28520581?dopt=Abstract

Read More
<< Go Back